1025899-41-5 Usage
Uses
Used in Organic Synthesis:
(1-Benzhydryl-azetidin-3-yl)-hydrazine is used as a reagent in organic synthesis for the formation of heterocyclic compounds and pharmaceutical intermediates. Its unique structure and reactivity contribute to the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
(1-Benzhydryl-azetidin-3-yl)-hydrazine is used as a pharmaceutical intermediate due to its potential role in the development of new drugs. Its unique chemical properties allow it to be a key component in the creation of innovative medications.
Used in Drug Development:
(1-Benzhydryl-azetidin-3-yl)-hydrazine has potential applications in the development of new drugs, particularly in the area of antitumor agents. Its biological activities, such as the ability to inhibit specific enzymes, make it a valuable compound for further research and development in medicine.
Used in Materials Science:
(1-Benzhydryl-azetidin-3-yl)-hydrazine is also studied for its potential applications in materials science. Its unique chemical structure may contribute to the development of new materials with specific properties for various industries.
Further research on (1-Benzhydryl-azetidin-3-yl)-hydrazine may reveal additional applications in the fields of medicine and materials science, expanding its use and significance in these areas.
Check Digit Verification of cas no
The CAS Registry Mumber 1025899-41-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,5,8,9 and 9 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1025899-41:
(9*1)+(8*0)+(7*2)+(6*5)+(5*8)+(4*9)+(3*9)+(2*4)+(1*1)=165
165 % 10 = 5
So 1025899-41-5 is a valid CAS Registry Number.
1025899-41-5Relevant academic research and scientific papers
BRUTON'S TYROSINE KINASE INHIBITORS
-
Page/Page column 84, (2014/05/24)
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
